6.
Ren S, Chen X, Wang Z, Zhao R, Wang J, Cui W
. Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. PLoS One. 2019; 14(2):e0211566.
PMC: 6358067.
DOI: 10.1371/journal.pone.0211566.
View
7.
OConnor K, Li-Chang H, Kalloger S, Peixoto R, Webber D, Owen D
. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2015; 39(4):472-8.
DOI: 10.1097/PAS.0000000000000333.
View
8.
Jeon S, Lee J, Joo I, Lee E, Park H, Jang J
. Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR Imaging-Retrospective Cross-sectional Study. Radiology. 2017; 284(1):77-87.
DOI: 10.1148/radiol.2016160586.
View
9.
Klau M, Mayer P, Bergmann F, Maier-Hein K, Hase J, Hackert T
. Correlation of Histological Vessel Characteristics and Diffusion-Weighted Imaging Intravoxel Incoherent Motion-Derived Parameters in Pancreatic Ductal Adenocarcinomas and Pancreatic Neuroendocrine Tumors. Invest Radiol. 2015; 50(11):792-7.
DOI: 10.1097/RLI.0000000000000187.
View
10.
Zlobec I, Berger M, Lugli A
. Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer. 2020; 123(5):700-708.
PMC: 7462864.
DOI: 10.1038/s41416-020-0954-z.
View
11.
Lugli A, Zlobec I, Berger M, Kirsch R, Nagtegaal I
. Tumour budding in solid cancers. Nat Rev Clin Oncol. 2020; 18(2):101-115.
DOI: 10.1038/s41571-020-0422-y.
View
12.
Jiang H, Yang Y, Qian Y, Shao C, Lu J, Bian Y
. Tumor Budding Score Is a Strong and Independent Prognostic Factor in Patients With Pancreatic Ductal Adenocarcinoma: An Evaluation of Whole Slide Pathology Images of Large Sections. Front Oncol. 2021; 11:740212.
PMC: 8668607.
DOI: 10.3389/fonc.2021.740212.
View
13.
Elbanna K, Jang H, Kim T
. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging. 2020; 11(1):58.
PMC: 7183518.
DOI: 10.1186/s13244-020-00861-y.
View
14.
Torphy R, Wang Z, True-Yasaki A, Volmar K, Rashid N, Yeh B
. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol. 2018; 2018.
PMC: 6262879.
DOI: 10.1200/PO.17.00121.
View
15.
Hruban R, Gaida M, Thompson E, Hong S, Noe M, Brosens L
. Why is pancreatic cancer so deadly? The pathologist's view. J Pathol. 2019; 248(2):131-141.
DOI: 10.1002/path.5260.
View
16.
Lawlor R, Veronese N, Nottegar A, Malleo G, Smith L, Demurtas J
. Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. Cancers (Basel). 2019; 11(1).
PMC: 6356259.
DOI: 10.3390/cancers11010113.
View
17.
Mayer P, Fritz F, Koell M, Skornitzke S, Bergmann F, Gaida M
. Assessment of tissue perfusion of pancreatic cancer as potential imaging biomarker by means of Intravoxel incoherent motion MRI and CT perfusion: correlation with histological microvessel density as ground truth. Cancer Imaging. 2021; 21(1):13.
PMC: 7816417.
DOI: 10.1186/s40644-021-00382-x.
View
18.
Fukukura Y, Kumagae Y, Higashi R, Hakamada H, Nagano H, Hidaka S
. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Pancreatology. 2020; 20(6):1155-1163.
DOI: 10.1016/j.pan.2020.07.009.
View
19.
Szalai L, Jakab A, Kocsmar I, Szirtes I, Kenessey I, Szijarto A
. Prognostic Ability of Tumor Budding Outperforms Poorly Differentiated Clusters in Gastric Cancer. Cancers (Basel). 2022; 14(19).
PMC: 9563769.
DOI: 10.3390/cancers14194731.
View
20.
Siegel R, Miller K, Jemal A
. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30.
DOI: 10.3322/caac.21590.
View